Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
United States
Dana-Farber Cancer Institute, Boston, Massachusetts Memorial Sloan Kettering Cancer Center, New York, New York Fox Chase Cancer Center, Philadelphia, Pennsylvania SCRI Oncology Partners, Nashville, Tennessee START San Antonio, San Antonio, Texas Canada
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta France
Gustave Roussy, Villejuif, Val-de-Marne Spain
Local Institution - 0015, Córdoba, Andalusia Local Institution - 0018, Barcelona, Barcelona [Barcelona]